Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
View Patent ↗An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
1. A method of reducing the amount of time required to provide a therapeutically effective amount of corticosteroid to a subject by inhalation of a corticosteroid-containing composition with a nebulizer, the method comprising the steps of: including a sulfoalkyl ether cyclodextrin in the composition in an amount sufficient to solubilize the corticosteroid to form an inhalable aqueous corticosteroid-containing solution; and administering the solution to the subject by inhalation with a nebulizer, wherein the amount of time required to provide a therapeutically effective amount of corticosteroid to the subject with the solution is reduced as compared to the amount of time required to provide a therapeutically effective amount of corticosteroid to the subject with a corticosteroid-containing suspension comprising the same amount or concentration of corticosteroid when the suspension and solution are administered under otherwise similar nebulization conditions;
wherein the sulfoalkyl ether cyclodextrin in the aqueous corticosteroid-containing solution has the structure:
wherein:
each R is —H or —(CH 2 ) 4 SO 3 Na;
wherein the average degree of substitution of —(CH 2 ) 4 SO 3 Na is 6.0 to 7.1 per cyclodextrin molecule; and
wherein the molar ratio of the sulfoalkyl ether cyclodextrin to the corticosteroid in the aqueous corticosteroid-containing solution is between 14:1 and 10,000:1.
2. The method of claim 1 , wherein
the corticosteroid in the aqueous corticosteroid-containing solution is budesonide.
3. The method of claim 1 , wherein the formulation comprises less than 5% wt. undissolved corticosteroid.
4. The method of claim 1 , comprising 23.5% wt./wt. or less of the sulfoalkyl ether cyclodextrin.
5. The method of claim 1 , wherein the sulfoalkyl ether cyclodextrin is present at a concentration of about 10 mg to about 500 mg of sulfoalkyl ether cyclodextrin per ml of formulation.
6. The method of claim 1 , wherein the formulation has a shelf-life of at least 6 months.
7. The method of claim 1 further comprising one or more other therapeutic agents independently selected from the group consisting of a β2-adrenoreceptor agonist, a dopamine (D2) receptor agonist, a topical anesthetic, an anticholinergic agent, IL-5 inhibitor, antisense modulator of IL-5, milrinone (1,6-dihydro-2-methyl-6-oxo-[3,4′-bipyridine]-5-carbonitrile), milrinone lactate, tryptase inhibitor, tachykinin receptor antagonist, leukotriene receptor antagonist, 5-lipoxygenase inhibitor, and anti-IgE antibody.
8. The method of claim 7 , wherein the corticosteroid is present in a molar excess over the other therapeutic agent.
9. The method of claim 7 , wherein the other therapeutic agent is present in a molar excess over the corticosteroid.
10. The method of claim 7 , wherein the sulfoalkyl ether cyclodextrin is present in a molar excess over the other therapeutic agent.
11. The method of claim 1 , wherein the corticosteroid in the aqueous corticosteroid-containing solution is present in an amount sufficient to provide a mean plasma AUCt of 160-1600 pg*h/ml.
12. A method of providing in a subject:
(a) a mean plasma AUCt of 150-1600 pg*h/ml for budesonide in an individual subject comprising: administering by inhalation to the subject a dose of 48-220 μg of budesonide dissolved in an aqueous budesonide solution, wherein the aqueous budesonide solution comprises a sulfoalkyl ether cyclodextrin; or
(b) a mean plasma AUCt, normalized for dose of budesonide, of at least 6 (pg*h/ml)/μg of budesonide, comprising: administering by inhalation to the subject a dose of 45 μg to 1000 μg of budesonide dissolved in an aqueous budesonide solution, wherein the aqueous budesonide solution comprises a sulfoalkyl ether cyclodextrin; or
(c) a mean AUCi, normalized for dose of budesonide, of at least 8 (pg*h/ml)/ug of budesonide, comprising: administering by inhalation to the subject 45 μg to 1000 μg of budesonide dissolved in an aqueous budesonide solution, wherein the aqueous budesonide solution comprises a sulfoalkyl ether cyclodextrin;
wherein the sulfoalkyl ether cyclodextrin has the structure:
wherein:
each R is —H or —(CH 2 ) 4 SO 3 Na;
wherein the average degree of substitution of —(CH 2 ) 4 SO 3 Na is 6.0 to 7.1 per cyclodextrin molecule; and
wherein the molar ratio of the sulfoalkyl ether cyclodextrin to budesonide in the aqueous budesonide solution is between 14:1 and 10,000:1.